Dyne Therapeutics, Inc. $DYN Shares Bought by Perceptive Advisors LLC

Perceptive Advisors LLC lifted its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 34.2% during the 1st quarter, Holdings Channel.com reports. The fund owned 4,668,839 shares of the company’s stock after buying an additional 1,189,895 shares during the period. Dyne Therapeutics makes up 1.7% of Perceptive Advisors LLC’s holdings, making the stock its 20th largest holding. Perceptive Advisors LLC’s holdings in Dyne Therapeutics were worth $84,646,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also modified their holdings of the company. Hilton Head Capital Partners LLC purchased a new position in Dyne Therapeutics in the 1st quarter valued at approximately $26,000. Strs Ohio purchased a new stake in Dyne Therapeutics during the fourth quarter worth $51,000. Aster Capital Management DIFC Ltd purchased a new stake in Dyne Therapeutics during the fourth quarter worth $84,000. Steward Partners Investment Advisory LLC grew its holdings in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after purchasing an additional 7,697 shares during the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $25.18 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 19.92 and a current ratio of 12.02. The stock has a fifty day moving average of $21.24 and a two-hundred day moving average of $18.87. The company has a market capitalization of $4.70 billion, a price-to-earnings ratio of -7.56 and a beta of 1.06. Dyne Therapeutics, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $26.26.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, analysts anticipate that Dyne Therapeutics, Inc. will post -3.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

DYN has been the subject of several research reports. Evercore set a $33.00 price target on Dyne Therapeutics in a research note on Friday, May 15th. Morgan Stanley lowered their price objective on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating on the stock in a research note on Friday. Royal Bank Of Canada raised their target price on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday. TD Cowen initiated coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating for the company. Finally, Wall Street Zen cut shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.42.

Insider Buying and Selling

In other news, Director Brian S. Posner bought 2,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was purchased at an average price of $16.94 per share, with a total value of $33,880.00. Following the purchase, the director owned 24,500 shares of the company’s stock, valued at $415,030. This trade represents a 8.89% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jason P. Rhodes sold 297,211 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the completion of the transaction, the director owned 2,962 shares in the company, valued at approximately $68,896.12. This trade represents a 99.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders purchased 9,000 shares of company stock worth $156,800 and sold 1,665,542 shares worth $36,321,576. 9.46% of the stock is currently owned by company insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.